Skip to main content
. 2010 Dec 22;4:1–15. doi: 10.2147/IJNRD.S14716

Table 4.

Pulsatile insulin infusion: impact of ACE inhibition

A. Normal population

  1. Average rate of loss of Ccreat ∼1 mL/min/year


B. Type 1 diabetic nephropathy patients

  1. Prior to 2000 ∼15–25 mL/min/year

  2. Addition of pulsatile insulin to DCCT protocol
    1. No ACE inhibition
      1. Control group loss = 5.3 mL/min/year
      2. Infusion group loss = 5.2 mL/min/year
    2. With ACE inhibition
      1. Control group (n = 25) ∼8 ± 1 mL/min/year (52 weeks = 7.1; 78 weeks = 8.9 mL/min/year)
      2. Infusion group (n = 20) ∼0.8 ± 0.2 mL/min/year (52 weeks = 0.96; 78 weeks = 0.60 mL/min/year)
      3. P values: unpaired t-test: 52 weeks <0.11; 78 weeks <0.02
      4. Wilcoxon rank sum test: 52 weeks <0.20; 78 weeks <0.01

C. Mean arterial pressure for patients with highest slope of loss of Ccreat baseline, endpoint

  1. DCCT protocol (control group, n = 10) 93.1 ± 2.3, 94.8 ± 3.1 mmHg

  2. Pulsatile IV (infusion group, n = 10) 91.8 ± 2.0, 91.3 ± 2.5 mmHg


D. Mean arterial pressure for patients with lowest slope of loss of Ccreat baseline, endpoint

  1. DCCT protocol (control group, n = 10) 103.1 ± 3.0, 109.9 ± 2.9 mmHg*

  2. Pulsatile IV (infusion group, n = 10) 100.7 ± 2.1, 99.9 ± 2.8 mmHg*

Note:

*

P < 0.05.